{
"description": "Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial",
"_filename": "example/Evidence-179635.json",
"package_name": "hl7.fhir.uv.ebm",
"statistic": [ {
"quantity": {
"value": 1.59
},
"sampleSize": {
"numberOfParticipants": 68
},
"description": "18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)",
"statisticType": {
"coding": [ {
"code": "STATO:0000245",
"system": "https://fevir.net/sevco",
"display": "Risk Ratio"
} ]
},
"numberAffected": 30,
"attributeEstimate": [ {
"type": {
"coding": [ {
"code": "STATO:0000700",
"system": "https://fevir.net/sevco",
"display": "p-value"
} ]
},
"quantity": {
"value": 0.01,
"comparator": "<"
},
"description": "p < 0.01"
} ]
} ],
"date": null,
"meta": {
"profile": [ "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-participant-flow-evidence" ],
"versionId": "7",
"lastUpdated": "2024-12-13T21:07:33.593Z"
},
"publisher": "Computable Publishing LLC",
"name": "ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial",
"useContext": [ {
"code": {
"code": "evidence-communication",
"system": "https://fevir.net/resources/CodeSystem/179423",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [ {
"code": "ComparativeParticipantFlowEvidence",
"system": "https://fevir.net/resources/CodeSystem/179423",
"display": "ComparativeParticipantFlowEvidence"
} ]
}
} ],
"copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"type": null,
"experimental": null,
"resourceType": "Evidence",
"variableDefinition": [ {
"description": "Participants in the opioid detoxification trial",
"variableRole": "population"
}, {
"description": "GroupAssignment: Lofexidine vs. Placebo",
"variableRole": "exposure",
"comparatorCategory": "false"
}, {
"observed": {
"type": "EvidenceVariable",
"display": "PartiicipantFlowMeasure: Dropout due to stopping intervention",
"reference": "EvidenceVariable/179636"
},
"description": "Dropout due to stopping intervention",
"variableRole": "outcome"
} ],
"title": "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial",
"package_version": "1.0.0-ballot2",
"author": [ {
"name": "Brian S. Alper"
} ],
"extension": [ {
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to",
"extension": [ {
"url": "type",
"valueCode": "cite-as"
}, {
"url": "targetMarkdown",
"valueMarkdown": "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2024-05-16. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635#json."
} ]
}, {
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to",
"extension": [ {
"url": "type",
"valueCode": "derived-from"
}, {
"url": "targetReference",
"valueReference": {
"type": "Citation",
"display": "18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal",
"reference": "Citation/179637"
}
} ]
} ],
"status": "active",
"id": "22ea3237-2e94-4f6c-9a8a-634dcea68771",
"kind": null,
"url": "https://fevir.net/resources/Evidence/179635",
"identifier": [ {
"type": {
"text": "FEvIR Object Identifier",
"coding": [ {
"code": "ACSN",
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"display": "Accession ID"
} ]
},
"value": "https://fevir.net/FOI/179635",
"system": "urn:ietf:rfc:3986",
"assigner": {
"display": "Computable Publishing LLC"
}
} ],
"version": null,
"contact": [ {
"telecom": [ {
"value": "support@computablepublishing.com",
"system": "email"
} ]
} ]
}